ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2634

The Prevalence of Autoimmune Disease in Families of Patients with Systemic Lupus Erythematosus (SLE). a Single Centre Study

Oseme Etomi1, Andrea Cove-Smith2, Ravindra Rajakariar3, Myles J. Lewis2,4,5,6, Angela Pakozdi2 and Debasish Pyne2, 1heumatology Department, Barth Health NHS foundation trust, London, United Kingdom, 2Barts Lupus Centre, Barts Health NHS Trust, London, United Kingdom, 3Bart's Lupus Center, Barts Health NHS Foundation Trust, London, United Kingdom, 4Experimental Medicine & Rheumatology, Queen Mary University of London, London, United Kingdom, 5Myles Lewis ([email protected]), London, United Kingdom, 6Rheumatology, Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and The London, School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: autoimmune diseases, Family studies and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 7, 2017

Title: Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster III: Therapeutics and Clinical Trial Design

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:

Studies to date have reported that up to 30% of lupus patient have a first degree relative with an autoimmune disorder (AD). The most recent study from the Danish registry (1) reports an increase in risk of lupus, rheumatoid arthritis (RA) , type 1 diabetes (T1DM) and inflammatory bowel disease in individuals with an SLE-affected first-degree relative . Here we describe the prevalence of ADs amongst family members in a multi ethnic lupus cohort.

Methods:

Questionnaires were distributed to consecutive lupus patients attending our Lupus clinic between April 2017 and June 2017. All patients fulfilled the 2012 SLICC ACR criteria for lupus. Patients were asked about their family history with specific questions on the presence of a range of ADs.

Results:

74 patients completed questionnaires. 24 were incomplete, the remaining 50 were analysed. The average age of patients with SLE was 41.6years (21- 78) 90% of the patients were female. South east Asians (40%) and afro- Caribbean (36%) represented the majority of our cohort. Others included Caucasian (14%), Turkish (4%), oriental (2%), Malaysian (2%) and one mixed race (2%) Caucasian-afro Caribbean.

13 (26%) patients with SLE had another autoimmune condition with RA the most common (n= 7 ,14%), followed by antiphospholipid syndrome (APS) (n =4 , 8%) , sjogrens (n=1) and hashimotos (n=1).

The prevalence of a second AD in lupus patients was highest in Afro-Caribbeans (n=16, 89%). Afro-Caribbean patients were significantly more likely to have another AD than South East Asians (n=7, 35%) (p=0.001) and Caucasians (n=1, 14%) (p=0.001).

A family history of AD was found in 17 patients (34%). SLE was the most prevalent AD in relatives with 8 cases (16%) identified, followed by RA in 5 (10%), T1DM (n=3), graves’ disease (n=3) and multiple sclerosis (n =2 ). Other AD identified were sjogrens, hashimotos and psoriasis (n=1). In 54% the family history was in a first degree relative, second degree relative in 37.5% and 3rd degree relatives in 8.3%. The majority of relatives with an autoimmune history were female ( 70.8%). There was no significant difference in the incidence of a family history of autoimmune disease between the various ethnic groups.

Conclusion:

Within our multi ethnic cohort of patients with SLE, RA was the most common second AD followed by APS. Afro-Caribbean were more likely to have a second AD than either south east Asians or Caucasians. SLE, RA, T1DM and Graves’ disease were the most common ADs found in family members. Ethnicity did not affect the likelihood of patients having a relative with an AD. Larger sampling is warranted for future studies.


Disclosure: O. Etomi, None; A. Cove-Smith, None; R. Rajakariar, None; M. J. Lewis, None; A. Pakozdi, None; D. Pyne, None.

To cite this abstract in AMA style:

Etomi O, Cove-Smith A, Rajakariar R, Lewis MJ, Pakozdi A, Pyne D. The Prevalence of Autoimmune Disease in Families of Patients with Systemic Lupus Erythematosus (SLE). a Single Centre Study [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/the-prevalence-of-autoimmune-disease-in-families-of-patients-with-systemic-lupus-erythematosus-sle-a-single-centre-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-prevalence-of-autoimmune-disease-in-families-of-patients-with-systemic-lupus-erythematosus-sle-a-single-centre-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology